CRA International,Inc. (CRAI)

On our desk, the recent Q2 print for CRAI reads as a classic beat-and-raise setup, delivering a record $210.8 million in revenue up 12.8% year-over-year. Management even lifted the fiscal 2026 guide to $805–820 million. However, the market reaction has been muted, with shares slipping after the print. Valuation is a real point of friction here; the stock is trading ~23.6% below its 52-week high, and some participants argue the recent rally already priced in a steep portion of this demonstrated growth. We are watching closely to see if earnings quality and margin expansion can catch up during the Q3 print around late October.

From a quantitative risk perspective, CRAI's underlying fundamentals present a dual narrative. While top-line momentum is supported by a sixth consecutive record quarter for the Antitrust and Competition Economics practice and international growth of 32.9%, we cannot ignore the balance-sheet metrics. Higher talent-related spending has weighed on first-half margins, and elevated receivables paired with revolver borrowings make cash conversion a critical watchpoint. Furthermore, technical positioning shows an invalidation trigger if a weekly close breaches below $155, which would surrender the bulk of the recent three-month recovery leg.

When evaluating consulting sector exposures like CRAI, our protocol focuses heavily on utilization rates and headcount scaling. Consultant headcount reached 968 at quarter end—a 3.3% year-over-year increase driven by over 60 new hires—while the utilization rate ticked up to 77% from 76% in Q2 2025. This indicates that organic demand across eight practices is successfully absorbing fresh talent, particularly capitalizing on global MandA activity reaching $1.6 trillion and AI complexity driving Forensic Services. Analysts assessing this model must weigh this structural demand amplification against ongoing wage pressures.